JournalArta
Wednesday, November 18, 2026 · JakartaS&P 7,305.04 ▼0.48%USD/IDR 18,241 ▼0.11%
JournalArta
Global Edition
beyond headlines
Advertisement

Hims & Hers Launches Five Unapproved Compounded Treatments

Hims & Hers Health is introducing five compounded treatments through its Peptides+ platform, although none of the specific products has FDA approval. The telehealth company says licensed providers will assess patients, while medical experts warn that evidence and dosing information remain limited for some peptides.

By matthew jonathan
November 18, 20263 min read
Hims & Hers Launches Five Unapproved Compounded Treatments
Hims & Hers Launches Five Unapproved Compounded Treatments

Hims & Hers Health has launched five compounded treatments in the United States through its Peptides+ platform. None of the company's specific products has Food and Drug Administration approval.

The telehealth company acknowledged uncertainty about how best to use peptides and how effective they are. Peptides are short chains of amino acids, and most lack evidence from robust human trials.

Hims & Hers will offer compounded formulations of sermorelin, glutathione and nicotinamide adenine dinucleotide, known as NAD+. It will also offer compounded vitamin B-12 and L-carnitine.

Compounding involves preparing a formulation at a pharmacy. Hims & Hers said its products are made in the United States by licensed pharmacies inspected by state pharmacy boards.

Advertisement

The company said more than 10,000 people joined an early access list within 15 days of its launch in late October.

Patients will receive provider assessments

Members will begin with an assessment of their health history and goals by a licensed provider trained in peptide therapies. The provider can tailor a plan if appropriate, the company said.

Dr. Anant Vinjamoori, the company's chief medical officer, said providers could adjust doses, consider other compounds or refer patients to other care. He also acknowledged gaps in the evidence.

“We don't have all of this data that we're used to having with compounds like this,” Vinjamoori said.

People with serious illnesses, including cardiovascular, liver and kidney disease, will not be candidates for the compounds for now, he said.

Advertisement

Patients can also use the company's Care+ service, which offers twice-a-year lab testing and around-the-clock messaging with providers trained in peptide therapy.

Experts question testing and doses

Joshua Kritzer, a chemistry professor at Tufts University, said a lack of large clinical trials makes it difficult to rule out rare, serious complications.

“Without actual testing, all you have is anecdotal information, and that's just not enough information to put a substance in your body,” Kritzer said.

Paul Knoepfler, a cell biology and human anatomy professor at UC Davis Health, said dosing is another uncertainty. Excessive amounts of a synthetic peptide could trigger harmful immune responses, he said.

Advertisement

Knoepfler said more contact with physicians is better. Providers should inform patients about risks and consider their existing conditions, cancer history and other medications, he said.

Federal policy eased restrictions

The launch follows an October policy from the Health and Human Services Department covering six unapproved peptides. The policy says the FDA will not take enforcement action against certain licensed pharmacies, federal facilities or physicians that compound and dispense them while formal rules are reviewed.

The policy does not constitute FDA approval of the peptides. It followed a 2023 FDA decision to restrict compounding of popular peptide formulations over safety, impurity and immune-reaction concerns.

Advertisement

Hims & Hers plans to add more US-made therapies, including BPC-157 and TB-500. Both peptides are unapproved, and most research on them has been conducted in animals rather than humans.

A 2026 systematic review screened 113 studies and found no eligible clinical outcome trials proving that intravenous or intramuscular NAD+ improves anti-aging, energy or wellness outcomes in humans.

In August, the FDA said it had received reports of adverse events in at least 30 patients after compounded intravenous glutathione treatments from different pharmacies.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage
  2. 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI
  3. 3NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur
  4. 4Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds
  5. 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings
Advertisement
Don't Miss

Latest News

All stories →
  1. Technology · GamingGrand Theft Auto VI Uses AMD Upscaling on Xbox Series SNov 18
  2. Lifestyle · Food & HealthResearchers Propose Raising Medicare’s Subsidized Cancer Care Visits to 12Nov 18
  3. World · EuropeEuropean Commission Proposes $49.4 Billion Ukraine LoanNov 18
  4. Lifestyle · EntertainmentNoa Nakada, Japanese Actress in Ultraman Teo, Dies at 23Nov 18
  5. Advertisement
  6. Markets · StocksAmazon and Google to Own 28.4% of Anthropic After IPONov 18
  7. Markets · StocksNvidia Shares Rise as Revenue Forecast Eases AI Demand FearsNov 18
  8. Markets · StocksAnthropic IPO Draws Wall Street Interest Despite AI Stock SlumpNov 18
  9. Technology · GamingBackbone Founder Plans to Play GTA VI With His MomNov 18